Cost Versus Value: Earnings Calls Spotlight US Pricing Reforms
Executive Summary
Pink Sheet has scoured big pharma annual results presentations to gauge the industry's reactions and concerns around the increasingly tough US drug pricing environment and proposed changes to the Affordable Care Act under the new Trump administration.
You may also be interested in...
Amid Pricing Criticism, Marathon 'Pausing' Emflaza Launch
Company plans to meet with caregivers and consider other options before moving forward.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.